Skip to content
All Sections
Subscribe Now
78°F
Saturday, August 24th 2024
Today's E-Edition
Home Page
Close Menu
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
SUBSCRIBE NOW
Close Menu
Morning Report in your inbox!
Sign Up
Subscribe
Account Settings
Contact Us
Log Out
Spoof a user
Morning Report in your inbox!
Sign Up
Subscribe
Search
Silicon Valley
78°F
Saturday, August 24th 2024
Today's E-Edition
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cellectis Inc.
< Previous
1
2
Next >
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
August 03, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
July 27, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
July 12, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
June 28, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
June 09, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
June 05, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
May 31, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
May 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
May 12, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
May 11, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
May 04, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 02, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
April 27, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
April 24, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
April 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
April 11, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
April 04, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
March 14, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 08, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
March 06, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
CLXT
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
March 01, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
February 07, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
February 03, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces Pricing of Follow-On Offering
February 03, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces Launch of Follow-On Offering
February 02, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
January 20, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
January 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
CLXT
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
December 29, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
December 28, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
December 22, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Tickers
CLLS
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close